Page 61 - 86_01
P. 61

ANALES                                                                            ted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope
                                                                                  Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost.
RANF                                                                              J. Virol.. 2015;89(12):6462-80.
                                                                                47. Perdiguero B, Gómez CE, Cepeda V, Sánchez-Sampedro L, García-Arriaza
   www.analesranf.com                                                             J, Mejías-Pérez E, et al. Virological and immunological characterization of
                                                                                  novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric
  T, et al. A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene      soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like parti-
  C6L enhances memory HIV-1-specific T-cell responses. PloS one.                  cles. J. Virol.. 2015;89(2):970-88.
  2011;6(8):e24244.                                                             48. Pantaleo G, Janes H, Karuna S, Grant S, Ouedraogo GL, Allen M, et al.
34. Perdiguero B, Gómez CE, Nájera JL, Sorzano CO, Delaloye J, González-          Safety and immunogenicity of a multivalent HIV vaccine comprising enve-
  Sanz R, et al. Deletion of the viral anti-apoptotic gene F1L in the HIV/AIDS    lope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b,
  vaccine candidate MVA-C enhances immune responses against HIV-1 an-             double-blind, placebo-controlled trial. Lancet HIV. 2019.
  tigens. PloS one. 2012;7(10):e48524.                                          49. Gómez CE, Nájera JL, Krupa M, Esteban M. The poxvirus vectors MVA and
35. Falivene J, Del Medico Zajac MP, Pascutti MF, Rodríguez AM, Maeto C,          NYVAC as gene delivery systems for vaccination against infectious diseases
  Perdiguero B, et al. Improving the MVA vaccine potential by deleting the        and cancer. Curr. Gen. Ther. 2008;8(2):97-120.
  viral gene coding for the IL-18 binding protein. PloS one.                    50. Gómez CE, Nájera JL, Krupa M, Perdiguero B, Esteban M. MVA and NYVAC
  2012;7(2):e32220.                                                               as vaccines against emergent infectious diseases and cancer. Curr. Gen.
36. García-Arriaza J, Gómez CE, Sorzano CO, Esteban M. Deletion of the vac-       Ther. 2011;11(3):189-217
  cinia virus N2L gene encoding an inhibitor of IRF3 improves the immuno-       51. Gómez CE, Perdiguero B, García-Arriaza J, Esteban M. Clinical applications
  genicity of modified vaccinia virus Ankara expressing HIV-1 antigens. J.        of attenuated MVA poxvirus strain. Expert review of vaccines.
  Virol.. 2014;88(6):3392-410.                                                    2013;12(12):1395-416.
37. García-Arriaza J, Nájera JL, Gómez CE, Sorzano CO, Esteban M. Immuno-       52. Harmon TM, Fisher KA, McGlynn MG, Stover J, Warren MJ, Teng Y, et al.
  genic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing      Exploring the Potential Health Impact and Cost-Effectiveness of AIDS Vaccine
  four HIV-1 antigens and potentiation by specific gene deletions. PloS one.      within a Comprehensive HIV/AIDS Response in Low- and Middle-Income
  2010;5(8):e12395.                                                               Countries. PloS one. 2016;11(1):e0146387.
38. García-Arriaza J, Arnaez P, Gómez CE, Sorzano CO, Esteban M. Improving      53. de Montigny S, Adamson BJS, Masse BR, Garrison LP, Jr., Kublin JG, Gilbert
  Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candi-              PB, et al. Projected effectiveness and added value of HIV vaccination cam-
  date MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking           paigns in South Africa: A modeling study. Sci Rep. 2018;8(1):6066.
  Interferon Signaling Pathways. PloS one. 2013;8(6):e66894.                    54. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J,
39. Nájera JL, Gómez CE, García-Arriaza J, Sorzano CO, Esteban M. Insertion       Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 in-
  of vaccinia virus C7L host range gene into NYVAC-B genome potentiates           fection in Thailand. N Engl J Med. 2009;361(23):2209-20.
  immune responses against HIV-1 antigens. PloS one. 2010;5(6):e11406.          55. Kim JH, Excler JL, Michael NL. Lessons from the RV144 Thai phase III
40. Kibler KV, Gómez CE, Perdiguero B, Wong S, Huynh T, Holechek S, et al.        HIV-1 vaccine trial and the search for correlates of protection. Annu Rev
  Improved NYVAC-based vaccine vectors. PloS one. 2011;6(11):e25674.              Med. 2015;66:423-37.
41. Quakkelaar ED, Redeker A, Haddad EK, Harari A, McCaughey SM, Duhen          56. Lin L, Finak G, Ushey K, Seshadri C, Hawn TR, Frahm N, et al. COMPASS
  T, et al. Improved innate and adaptive immunostimulation by genetically         identifies T-cell subsets correlated with clinical outcomes. Nat Biotechnol.
  modified HIV-1 protein expressing NYVAC vectors. PloS one.                      2015;33(6):610-6.
  2011;6(2):e16819.                                                             57. Altenburg AF, van de Sandt CE, Li BWS, MacLoughlin RJ, Fouchier RAM,
42. Gómez CE, Nájera JL, Sánchez R, Jiménez V, Esteban M. Multimeric soluble      van Amerongen G, et al. Modified Vaccinia Virus Ankara Preferentially Tar-
  CD40 ligand (sCD40L) efficiently enhances HIV specific cellular immune          gets Antigen Presenting Cells In Vitro, Ex Vivo and In Vivo. Sci Rep.
  responses during DNA prime and boost with attenuated poxvirus vectors           2017;7(1):8580.
  MVA and NYVAC expressing HIV antigens. Vaccine. 2009;27(24):3165-             58. Guerra S, González JM, Climent N, Reyburn H, López-Fernández LA, Nájera
  74.                                                                             JL, et al. Selective induction of host genes by MVA-B, a candidate vaccine
43. Moutaftsi M, Salek-Ardakani S, Croft M, Peters B, Sidney J, Grey H, et al.    against HIV/AIDS. J. Virol.. 2010;84(16):8141-52.
  Correlates of protection efficacy induced by vaccinia virus-specific CD8+     59. Gómez CE, Perdiguero B, Jiménez V, Filali-Mouhim A, Ghneim K, Haddad
  T-cell epitopes in the murine intranasal challenge model. Eur J Immunol.        EK, et al. Systems analysis of MVA-C induced immune response reveals its
  2009;39(3):717-22.                                                              significance as a vaccine candidate against HIV/AIDS of clade C. PloS one.
44. Di Pilato M, Mejías-Pérez E, Gómez CE, Perdiguero B, Sorzano CO, Esteban      2012;7(4):e35485.
  M. New vaccinia virus promoter as a potential candidate for future vaccines.  60. Climent N, Guerra S, García F, Rovira C, Miralles L, Gómez CE, et al. Den-
  J. Gen. Virol.. 2013;94(Pt 12):2771-6.
45. Di Pilato M, Sánchez-Sampedro L, Mejías-Pérez E, Sorzano CO, Esteban
  M. Modification of promoter spacer length in vaccinia virus as a strategy to
  control the antigen expression. J. Gen. Virol.. 2015;96(8):2360-71
46. Hulot SL, Korber B, Giorgi EE, Vandergrift N, Saunders KO, Balachandran
  H, et al. Comparison of Immunogenicity in Rhesus Macaques of Transmit-

MVA-B como candidato vacunal frente al VIH/SIDA: de la inves-                   59
tigación básica a los ensayos clínicos profiláctico y terapéutico.

Carmen Elena Gómez Rodríguez
An Real Acad Farm Vol. 86. Nº 1 (2020) · pp. 29 -60
   56   57   58   59   60   61   62   63   64   65   66